$279,123.18 ownership Payment -- Gilead Sciences to Dr. Rachel Parker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Gilead Sciences made a $279.1K ownership payment to Rachel Parker, a Infectious Disease specialist in Harrisburg, PA. The payment was associated with Stelara. The total payment amount of $279,123.18 is significant, indicating a substantial financial relationship. This payment is categorized as 'Ownership or Investment Interest,' suggesting a long-term financial stake rather than a one-time fee. The payment involves Gilead Sciences and is associated with the drug Stelara, highlighting a specific product focus.

Patient Guidance: What This Payment Means for You

This information details a financial relationship between a physician and a pharmaceutical company, which may influence treatment decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interests are a common form of financial relationship in the pharmaceutical industry, but the substantial amount here warrants attention within the Infectious Disease specialty.

Regulatory Context: Sunshine Act Requirements

Payments for ownership or investment interests are reportable under the Sunshine Act, requiring transparency in financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• gilead-sciences
• infectious-disease
• stelara
• physician-payment
• cms-open-payments

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $279.1K payment for?

This was a ownership payment of $279.1K from Gilead Sciences to Rachel Parker, categorized as "Ownership or Investment Interest". It was associated with Stelara. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Rachel Parker accept pharmaceutical money?

Yes, Rachel Parker received this $279.1K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Rachel Parker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $279.1K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Infectious Disease?

To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Rachel Parker's relationship with Gilead Sciences?

The payment date is recent, falling in April 2024. This $279.1K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Infectious Disease?

The physician, Rachel Parker, is located in Harrisburg, PA.

What should patients do after learning about this payment?

This information details a financial relationship between a physician and a pharmaceutical company, which may influence treatment decisions.

What else should I know about this ownership payment?

The payment ID is OP-MNEUO31Y-Z9PTGK.

Related Reports

• View Dr. Rachel Parker's full payment report
• Gilead Sciences full spending report
• Browse all Infectious Disease payments
• Browse all payments in Pennsylvania
• Search for other payments